Seborrhea Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Arcutis Biotherapeutics, Cutanea Life Sciences Inc., Vyome Therapeutics

DelveInsight's, "Seborrhea - Pipeline Insight, 2025," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Seborrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight reports that over three key companies are actively engaged in the development of more than three treatment therapies for Seborrhea.

Seborrhea Overview:

Seborrhea is a long-term inflammatory skin disorder marked by the accumulation of oily, flaky scales. It often appears as yellowish, crusty, and itchy patches, particularly on the scalp-commonly referred to as dandruff. Other commonly affected areas include the face, ears, eyebrows, eyelids, belly button, and genital region. The condition can be classified as either primary, which is inherited, or secondary, which is more prevalent and often has no clearly identifiable cause. Factors such as hormonal changes, stress, and the presence of a yeast-like fungus are believed to contribute to its onset. Seborrhea can impact people across all age groups-from infants to older adults-and is more frequently observed in males and individuals with oily skin.

Request for a detailed insights report on Seborrhea pipeline insights @ https://www.delveinsight.com/report-store/sebohrrea-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

"Seborrhea Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Seborrhea Therapeutics Market.

Key Takeaways from the Seborrhea Pipeline Report

*
DelveInsight's Seborrhea pipeline report highlights an active and evolving landscape, with more than three companies working on the development of therapies for Seborrhea. Leading companies such as Arcutis Biotherapeutics, Cutanea Life Sciences Inc., Vyome Therapeutics, and others are investigating new drug candidates aimed at enhancing treatment options for the condition.

*
Among the promising therapies in development is ARQ154 (Topical Roflumilast Foam), along with others in various stages of clinical progress.

*
In a significant advancement, the U.S. FDA approved Zoryve (roflumilast) topical foam, 0.3%, in December 2023 for the treatment of seborrheic dermatitis in patients aged 9 and above. This marks the first approval of a therapy with a new mechanism of action for this condition in over 20 years.

Seborrhea Pipeline Analysis

The report provides insights into:

*
The report provides detailed insights into the key companies that are developing therapies in the Seborrhea Market.

*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Seborrhea treatment.

*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Seborrhea market.

Download our free sample page report on Seborrhea pipeline insights [https://www.delveinsight.com/sample-request/sebohrrea-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Seborrhea Emerging Drugs

*
ARQ154 (Topical Roflumilast Foam): Arcutis Biotherapeutics, Inc.

Since 2011, the U.S. Food and Drug Administration (FDA) has approved roflumilast for systemic use to help reduce the risk of exacerbations in chronic obstructive pulmonary disease (COPD). Arcutis Biotherapeutics Inc. recently reported positive topline results from its Phase 2 clinical trial evaluating ARQ-154, a topical foam formulation of roflumilast, as a potential treatment for seborrheic dermatitis. This foam-based version, ARQ-154, is a highly potent and selective PDE4 inhibitor.

Seborrhea Companies

Multiple leading companies are actively working on therapies for seborrhea. Among them, Arcutis Biotherapeutics Inc. has a drug candidate that is the furthest along in development, currently in Phase II clinical trials.

DelveInsight's report covers around 3+ products under different phases of clinical development like

*
Late stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I) along with the details of

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Seborrhea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Seborrhea Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Seborrhea Therapies and Key Companies: Seborrhea Clinical Trials and advancements [https://www.delveinsight.com/report-store/sebohrrea-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Seborrhea Pipeline Therapeutic Assessment

- Seborrhea Assessment by Product Type

- Seborrhea By Stage

- Seborrhea Assessment by Route of Administration

- Seborrhea Assessment by Molecule Type

Download Seborrhea Sample report to know in detail about the Seborrhea treatment market @ Seborrhea Therapeutic Assessment [https://www.delveinsight.com/sample-request/sebohrrea-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Seborrhea Current Treatment Patterns

4. Seborrhea - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Seborrhea Late-Stage Products (Phase-III)

7. Seborrhea Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Seborrhea Discontinued Products

13. Seborrhea Product Profiles

14. Seborrhea Key Companies

15. Seborrhea Key Products

16. Dormant and Discontinued Products

17. Seborrhea Unmet Needs

18. Seborrhea Future Perspectives

19. Seborrhea Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Seborrhea Pipeline Reports Offerings [https://www.delveinsight.com/report-store/sebohrrea-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=seborrhea-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-arcutis-biotherapeutics-cutanea-life-sciences-inc-vyome-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.